Recombinant Human BAFF Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0347
Recombinant Human BAFF Protein (Fc Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0347
Product Overview
| Tag | Fc |
| Host Species | Human |
| Accession | Q9Y275 |
| Synonym | BAFF, BLYS, CD257, DTL, TALL-1, TALL1, THANK, TNFSF20, ZTNF4 |
| Background | B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors is a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and SjÖgren's syndrome (SS). BLyS as an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
| Description | A DNA sequence encoding the soluble form of human BAFF (Q9Y275-1) (Ala 134-Leu 285) was fused with the Fc region of human IgG1 at the N-terminus. |
| Source | HEK293 |
| Predicted N Terminal | Glu 20 |
| AA Sequence | Ala 134-Leu 285 |
| Molecular Weight | The recombinant human BAFF/Fc is a disulfide-linked homodimeric protein. The reduced monomer consists of 389 a.a. and has a predicted molecular mass of 43.7 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhBAFF/Fc monomer is approximately 48-55 kDa due to glycosylation. |
| Purity | >95% as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Bioactivity | 1. Measured by its binding ability in a functional ELISA. Immobilized recombinant human BAFF at 1 ug/mL (100 ul/well) can bind human TNFRSF17. The EC50 of human TNFRSF17 is 0.07 ug/mL.2. Measured in a cell proliferation assay in mouse splenocytes. The ED50 for this effect is typically 0.6-3.2 ng/mL. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
